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Endocannabinoid Tone Regulates Human
Sebocyte Biology
No´ra Za´ka´ny1,8, Attila Ola´h1,8, Arnold Markovics1, Erika Taka´cs1, Andrea Aranya´sz1, Simon Nicolussi2,
Fabiana Piscitelli3, Marco Allara`3, A´gnes Po´r4, Ilona Kova´cs4, Christos C. Zouboulis5, Ju¨rg Gertsch2,
Vincenzo Di Marzo3, Tama´s Bı´ro´6,9 and Tama´s Szabo´7,9
We have previously shown that endocannabinoids (eCBs) (e.g., anandamide) are involved in the maintenance of
homeostatic sebaceous lipidproduction inhuman sebaceous glands and that eCB treatmentdramatically increases
sebaceous lipid production. Here, we aimed to investigate the expression of the major eCB synthesizing and
degrading enzymes and to study the effects of eCB uptake inhibitors on human SZ95 sebocytes, thus exploring the
role of the putative eCB membrane transporter, which has been hypothesized to facilitate the cellular uptake and
subsequent degradation of eCBs. We found that the major eCB synthesizing (N-acyl phosphatidylethanolamine-
specific phospholipase D, and diacylglycerol lipase-a and -b) and degrading (fatty acid amide hydrolase,
monoacylglycerol lipase) enzymes are expressed in SZ95 sebocytes and also in sebaceous glands (except for
diacylglycerol lipase-a, the staining of whichwas dubious in histological preparations). eCB uptake-inhibitionwith
VDM11 inducedamoderate increase in sebaceous lipidproductionandalsoelevated the levelsof variouseCBsand
related acylethanolamides. Finally, we found that VDM11 was able to interfere with the proinflammatory action of
the TLR4 activator lipopolysaccharide. Collectively, our data suggest that inhibition of eCB uptake exerts
anti-inflammatory actions and elevates both sebaceous lipid production and eCB levels; thus, these inhibitors
might be beneficial in cutaneous inflammatory conditions accompanied by dry skin.
Journal of Investigative Dermatology (2018) 138, 1699e1706; doi:10.1016/j.jid.2018.02.022
INTRODUCTION
Sebaceous glands (SGs) are important players and regulators of
human skin homeostasis. In addition to their obvious function,
that is, production of lipid-rich sebum, by which they contribute
to the cutaneous lipid barrier and thermoregulation, they also
play a role in the endocrine and immune systems of the skin and
serve as stem cell reservoirs (Dajnoki et al., 2017; Lupi, 2008;
Porter, 2001; To´th et al., 2011; Zouboulis et al., 2008, 2014).
Their clinical significance is also remarkably high, because
overproduction and pathologically altered composition of
sebum in seborrhea is a key step in the pathogenesis of acne, one
of the most prevalent human skin diseases (Kurokawa et al.,
2009; To´th et al., 2011; Zouboulis et al., 2008, 2014). On the
other hand, lack of sufficient sebum production in adulthood
may contribute to dry skin syndrome, xerosis, or even skin aging
and atopic dermatitis (AD) (Kim et al., 2014;Mischo et al., 2014;
Shi et al., 2015; Zampeli et al., 2012; Zouboulis and
Boschnakow 2001). Moreover, the unique composition of
sebum is thought to play an important role in regulating the
growth of the cutaneous microbiota by restricting unwanted
microbes and promoting preferred ones, thus making
homeostatic SG functions important orchestrators of skin-
microbiota crosstalk (Pappas, 2009). Hence, via the subsequent
pathological alterations in the cutaneousmicrobiota, disorders of
sebaceous lipid production (SLP) may contribute to the patho-
genesis of several diseases, including AD (Shi et al., 2015).
Therefore, a better understanding of the (dys)regulation of SG
biologyand identification of additional regulators of homeostatic
SLP are clinically relevant topics of investigative dermatology.
Unfortunately, human SGs are challenging to study, because
primary sebocytes cannot be kept in culture for more than a few
passages, and there are no adequate animal model systems for
assessing thewhole complexity of human SGbiology (To´th et al.,
2011; Zouboulis et al., 2008, 2014). Therefore, in this study, we
used the human immortalized SZ95 sebocyte cell line
(Zouboulis et al. 1999),which is awidelyacceptedmodel system
for studying human SG functions in vitro (To´th et al., 2011;
Zouboulis et al., 2008, 2014).
A growing body of evidence suggests that SGs are not only
“innocent” targets of the complex cutaneous neuroendocrine
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system (Slominski, 2005; Slominski and Wortsman, 2000),
but also act as its master regulators by producing several
hormones and paracrine signal molecules (e.g., androgen
hormones, corticotropin-releasing hormone, several adipo-
kines, etc.) (Kova´cs et al., 2016; To´th et al., 2011; Zouboulis
et al., 2008, 2014). Furthermore, we have previously shown
that, besides the aforementioned regulators, human SGs are
also important players in the endocannabinoid system (ECS)
of the skin (Dobrosi et al., 2008; Ola´h and Bı´ro´, 2017).
The ECS is a complex signaling system, comprising
endogenous ligands (i.e., the endocannabinoids [eCBs]
such as arachidonoylethanolamide [AEA], also known as
anandamide; 2-arachidonoylglycerol [2-AG]); and receptors
(e.g., CB1 and CB2, etc.) and multiple enzymes involved in
the synthesis (e.g., N-acyl phosphatidylethanolamine-
specific phospholipase D [NAPE-PLD], diacylglycerol
lipase [DAGL]-a and -b, etc.) and degradation (e.g., fatty
acid amide hydrolase [FAAH], monoacylglycerol lipase
[MAGL]) of the eCBs and related non-eCB mediators (such
as monoacylglycerols and acylethanolamides, such as pal-
mitoylethanolamide [PEA], oleoylethanolamide [OEA],
etc.). Moreover, a putative eCB membrane transport mech-
anism (usually referred to as putative eCB membrane
transporter [EMT]), postulated to facilitate cellular uptake
and release of AEA and 2-AG, also belongs to this system
(Chicca et al., 2012; Ligresti et al., 2016; Maccarrone,
2017; Maccarrone et al., 2015; Nicolussi and Gertsch,
2015; Solymosi and Ko¨falvi, 2016). We have previously
shown that human SGs are capable of producing the major
eCBs (namely AEA and 2-AG), and we could also show, in
line with the early data of Sta¨nder et al. (2005) that SGs
express CB1 (mostly in differentiated cells) and CB2 re-
ceptors (predominantly in proliferating, basal layer sebo-
cytes) (Dobrosi et al., 2008; Sta¨nder et al., 2005). Moreover,
we found that locally produced eCBs, acting through a CB2-
coupled signaling pathway, are key players in the mainte-
nance of the homeostatic SLP, because selective gene
silencing of CB2 significantly reduced basal SLP of SZ95
sebocytes, whereas eCB treatment of the cells led to greatly
increased lipogenesis (Dobrosi et al., 2008). In this way, we
provided evidence, to our knowledge previously unre-
ported, that human SGs have a functionally active ECS, and
that treatment of human sebocytes with exogenously
administered AEA or 2-AG dramatically increases SLP.
However, we did not have any data about either the
expression of the enzyme apparatus involved in the syn-
thesis and degradation of the eCBs or the role of the local
eCB tone created by these enzymes in human sebocytes.
Thus, within the confines of this highly focused study, we
aimed to explore the expression of the major members of
the ECS in vitro in human sebocytes and in situ in human
skin, and we also wanted to investigate whether pharma-
cological modulation of eCB homeostasis was indeed able
to regulate SLP.
RESULTS
Major enzymes of eCB metabolism are expressed in cultured
human sebocytes and in situ in human SGs
First, by using human immortalized SZ95 sebocytes, we
investigated expression of the major enzymes involved in the
synthesis and degradation of AEA (NAPE-PLD and FAAH,
respectively) and 2-AG (DAGLa and -b and MAGL, respec-
tively). We found that, irrespective of the confluence level of
the cells, all the mentioned enzymes were expressed in hu-
man sebocytes both at the mRNA (quantitative PCR) and
protein (Western blot) levels (see Supplementary
Figure S1aed online). To further confirm these results, we
also investigated their expression in human skin samples
(appropriately labeled positive controls are shown in
Supplementary Figure S2 online). With the sole exception of
DAGLa, which exhibited questionable expression compared
with the endogenous positive control sweat glands (Czifra
et al., 2012), our findings nicely confirmed our in vitro data
about the expression of these enzymes in human SGs in situ
(Figure 1).
Sebocytes exhibit a pharmacologically inhibitable eCB
uptake process
Next, we assessed whether pharmacologically inhibitable
AEA uptake by the putative EMT (Chicca et al., 2012;
Nicolussi and Gertsch, 2015) was observable in these cells.
By monitoring the uptake of radiolabeled [3H]AEA by the
cells, we found that acute inhibition (15 minutes, 10 mmol/L)
of AEA cellular uptake using the reference eCB transport in-
hibitor UCM707 (Lo´pez-Rodrı´guez et al., 2003; Rau et al.,
2016) was able to significantly alter the eCB uptake pro-
cess. UCM707 reduced the intracellular [3H]AEA signal,
which was accompanied by a significant increase in extra-
cellular [3H]AEA levels compared with vehicle control. As a
consequence of [3H]AEA uptake inhibition, the overall hy-
drolysis of [3H]AEA by FAAH to arachidonic acid and [3H]
ethanolamine was reduced (Figure 2a). Theoretically, a
decrease of [3H]AEA uptake and [3H]ethanolamine levels
could be explained not only by the inhibition of the eCB
transport process, but also by nonspecific inhibition of FAAH
resulting in a reduced driving force for [3H]AEA uptake
(Chicca et al., 2012; Nicolussi et al., 2014a). To exclude this
possibility, we assessed how two different EMT inhibitors
(UCM707 and VDM11, both widely used to abrogate cellular
uptake of eCBs) (De Petrocellis et al., 2000; Lo´pez-Rodrı´guez
et al., 2003) influence FAAH activity in SZ95 sebocytes
compared with the reference FAAH inhibitor URB597 (Mor
et al., 2004). We found that SZ95 sebocytes exhibit very
low constitutive FAAH activity (2.32  0.25 pmol/minute/mg
protein, n ¼ 10), and that, unlike URB597, neither UCM707
nor VDM11 exerted substantial FAAH inhibition (half
maximal inhibitory concentration values were above 25
mmol/L for both EMT inhibitors, whereas the half maximal
inhibitory concentration of URB597 was below 100 nmol/L)
(see Supplementary Table S1 online). Taken together, these
findings suggest that in human sebocytes, eCB uptake can be
inhibited by VDM11, most likely in a FAAH-independent
manner.
The EMT plays a role in the degradation of eCBs in human
sebocytes
Next, we investigated the eCB transport process using one
of the aforementioned EMT inhibitors, VDM11 (De
Petrocellis et al., 2000). Cells were treated with this com-
pound or vehicle for 24 hours, and eCB content of the
samples was analyzed by liquid chromatography-mass
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spectrometry. We found that VDM11 treatment significantly
increased AEA content of the samples (Figure 2b), whereas
elevation of 2-AG concentration did not reach statistical
significance (Figure 2c). Besides the two major eCBs, we
also investigated the presence and potential alterations of
two ECS-related acylethanolamides, PEA and OEA. We
found that treatment by VDM11 tended to increase PEA and
significantly elevated OEA concentrations (Figure 2d and e).
Collectively, these data provided evidence that administra-
tion of VDM11 can increase the levels of certain eCBs
and eCB-like mediators in human sebocytes. These
results suggest that VDM11 might therefore promote ho-
meostatic eCB and eCB-like mediator signaling in these
cells.
Administration of eCB membrane transport inhibitors
mimics lipogenic actions of direct eCB treatment, whereas
selective FAAH inhibition does not influence SLP
It is well described that direct eCB treatment of sebocytes
results in dramatically increased SLP (Dobrosi et al., 2008;
Ola´h et al., 2014, 2016b). Thus, next we wanted to assess
how treatment with eCB uptake inhibitors influences the
functions of SGs. Using noncytotoxic concentrations (deter-
mined by MTT assay; see Supplementary Figure S3 online) of
the aforementioned VDM11, we explored its effect on SLP.
By using fluorescent Nile Red staining, we found that its low
micromolar concentrations induced a moderate but
significant increase in SLP after 48-hour treatments
(Figure 3a). Repetition of the experiment with AM404
Figure 1. Major enzymes of the
endocannabinoid metabolism are
expressed in human sebaceous glands
in situ. Immunohistochemistry of
human skin sections was performed as
described in the Supplementary
Materials. Specific immunopositivity
was visualized by 3,30-
diaminobenzidine (brown color), and
nuclei were counterstained with
hematoxylin (blue color). Original
magnifications ¼ 100 in the left
column and 400 in the middle and
right columns. Scale bars ¼ 200 mm in
the left column and 50 mm in the
middle and right columns. Arrows
indicate sweat glands (endogenous
positive control for DAGLa), and
arrowheads mark sebaceous glands on
the same image. Negative controls
(right column) were obtained by
omitting the primary antibody in all
cases. DAGL, diacylglycerol lipase;




phospholipase D, NC, negative
control.
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(another well-known AEA uptake inhibitor) (Beltramo et al.,
1997; Nicolussi and Gertsch, 2015) yielded very similar re-
sults (see Supplementary Figure S4a and b online). Although
both VDM11 and AM404 mimicked the lipogenic actions of
the prototypic eCB AEA (Dobrosi et al., 2008), their effi-
ciencies at elevating SLP were far exceeded by direct AEA
treatment (Figure 3a).
As discussed, several lines of evidence show that eCB
uptake inhibitors may concentration-dependently inhibit not
only the putative EMT but FAAH as well (Beltramo et al.,
1997; Chicca et al., 2017; Nicolussi and Gertsch, 2015).
Although our current measurements of the FAAH activity of
sebocytes already provided strong evidence that (i) SZ95
sebocytes exhibit very low constitutive FAAH activity and (ii)
in SZ95 sebocytes, both UCM707 and VDM11 can be used at
10 mmol/L without the risk of having substantial impact on
FAAH activity (see Supplementary Table S1), we also inten-
ded to investigate biological effects of the selective reference
FAAH inhibitor URB597 (Mor et al., 2004). We found that
Figure 2. Effects of the inhibitors of the putative endocannabinoid
membrane transporter in human sebocytes. (a) AEA transport measurement.
Cells were treated with the reference AEA uptake inhibitor UCM707 or
vehicle for 15 minutes, and intra- and extracellular amounts of radiolabeled
AEA or EtNH2 were detected as described in the Supplementary Materials.
Results are expressed as the percentage of vehicle control (100%, solid line)
as mean  standard error of the mean of three independent experiments, each
run in triplicate. (bee) AEA, 2-AG, PEA, and OEA determinations of the
samples (i.e., cells and their supernatants together) were performed as
described in the Supplementary Materials. Results are expressed as mean 
standard error of the mean of 3 or 4 independent cultures. *P < 0.05, **P <
0.01 and ***P < 0.001 mark significant differences compared with the vehicle
control. 2-AG, 2-arachidonoylglycerol; AEA, N-arachidonoylethanolamine
(i.e., anandamide); EtNH2, ethanolamine; EMT, (putative) endocannabinoid
membrane transporter; M, mol/L; n.s., not significant; OEA,
oleoylethanolamide; PEA, palmitoylethanolamide.
Figure 3. Noncytotoxic concentrations of VDM11 moderately but
significantly increase sebaceous lipid synthesis and exert remarkable anti-
inflammatory effects. (a) Sebaceous lipid production of SZ95 sebocytes was
assessed by Nile Red staining after 48-hour treatments. Results are expressed
as the percentage of the vehicle control (100%, solid line) as mean  standard
error of the mean of four independent determinations. One additional
experiment yielded similar results. **P < 0.01 and ***P < 0.01 mark
significant differences compared with the vehicle control. ###P < 0.001.
(b) Quantitative PCR. IL-1a, IL-1b, IL-6, IL-8 and TNF-a mRNA expressions
were determined after 3-hour LPS treatment with or without VDM11. Data
are presented by using the DDCT method regarding 18S RNA-normalized
mRNA expressions of the vehicle control as 1 (solid line). Data are expressed
as mean  standard deviation of three determinations. One additional
experiment yielded similar results. **P < 0.01 and ***P < 0.001, as indicated.
(c) ELISA. IL-6 and IL-8 content of the sebocyte supernatants was determined
after 24-hour LPS treatment with or without VDM11. Data are expressed as
mean  standard deviation of three determinations. Two additional
experiments yielded similar results. ***P < 0.001, as indicated. AEA,
N-arachidonoylethanolamine (i.e., anandamide); LPS, lipopolysaccharide;
M, mol/L; n.s., not significant compared with the vehicle control.
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administration of URB597 led to a different cell physiology
outcome than application of VDM11 and AM404. Indeed,
our data showed that noncytotoxic concentrations (MTT
assay, see Supplementary Figure S5a online) of URB597 did
not influence SLP (48-hour treatments, see Supplementary
Figure S5b) compared with the vehicle control group, indi-
cating that abrogation of eCB uptake, but not inhibition of
their FAAH-mediated intracellular degradation, leads to the
elevation of the SLP. Such lack of effect by URB597 can most
likely be ascribed to the aforementioned very low levels of
FAAH activity in SZ95 sebocytes.
Lipogenic action of direct AEA treatment is not further
increased by co-administration of VDM11
Next, we assessed how co-administration of AEA and
VDM11 affect SLP. We found that VDM11 was unable to
further promote the AEA-induced, already elevated SLP (see
Supplementary Figure S6 online) of human sebocytes, sug-
gesting that the pro-lipogenic eCB signaling activated by 30
mmol/L AEA is exhaustive and has no further “reserve
capacity.”
Up to 10 mmol/L, VDM11 does not induce apoptosis of
human sebocytes
Elevation of SLP is the hallmark of sebocyte differentiation,
which is usually followed by programmed cell death
(Dobrosi et al., 2008; Fischer et al., 2017; To´th et al., 2011;
Zouboulis et al., 2008, 2014). Because VDM11 was shown
to moderately promote SLP (Figure 3a, and see
Supplementary Figure S4b), we also wanted to know if it
induced early apoptotic processes. We found that, although
the most effective lipogenic concentration of VDM11 tended
to decrease mitochondrial membrane potential in course of
48-hour treatments (see Supplementary Figure S7 online), this
did not reach the level of significance, suggesting that within
the studied timeframe, it may indeed be devoid of obvious
pro-apoptotic effects.
VDM11 suppresses lipopolysaccharide (LPS)-induced
proinflammatory cytokine expression of human sebocytes
From a clinical point of view, induction of a moderate (not
seborrheic or acnegenic) increase in the homeostatic SLP
would be highly desirable in the treatment of skin dryness
(Kim et al., 2014; Mischo et al., 2014; Shi et al., 2015;
Zampeli et al., 2012; Zouboulis and Boschnakow, 2001).
Thus, our results suggest that administration of VDM11 (and
probably other EMT inhibitors too) may have beneficial ef-
fects in such conditions. Considering that skin dryness is
frequently accompanied by cutaneous inflammation (e.g., in
the case of AD) (Peng and Novak, 2015; Sugiura et al., 2014),
we finally investigated how VDM11 affects immune proper-
ties of human sebocytes. To this end, we applied LPS (5 mg/
ml, 3-hour treatments) (Ola´h et al., 2016b) to induce a
proinflammatory response. Co-administration of VDM11 (10
mmol/L) efficiently suppressed LPS-induced expression of
IL-1a, IL-1b, IL-6, IL-8, and TNF-a by human sebocytes
(quantitative PCR) (Figure 3b). Moreover, as shown by sub-
sequent ELISA analyses, VDM11 treatment significantly
suppressed LPS-induced release of IL-6 and led to only a
minor, nonsignificant decrease in IL-8 secretion (24-hour
treatments) (Figure 3c). Concentrations of the other three
cytokines were below (TNF-a) or around (IL-1a and IL-1b) the
detection limit of the respective assays (data not shown).
DISCUSSION
Skin dryness and the often accompanying overwhelming
cutaneous inflammatory processes (e.g., in AD, etc.) can
dramatically impair quality of life of many patients. On the
other hand, appropriate moisturization and emollient treat-
ment of the skin can alleviate symptoms, and in some cases,
they are even able to prevent the onset of AD (Hoppe et al.,
2015; Ola´h et al., 2017; Sawatzky et al., 2016; Sugiura et al.,
2014). Although inappropriate epidermal ceramide produc-
tion is thought to be the most important player in these
processes, a growing body of evidence now supports the
concept that dysregulation of SG functions and the subse-
quent alterations in the SLP are also fundamental. Indeed,
sebostasis, SG hypoplasia, and reduced SLP (with patholog-
ically reduced squalene and wax ester content) were shown
to occur in AD, and an inverse correlation between the
prevalence of acne and AD (the former characterized by
increased, and the latter by decreased, sebum production)
was also observed (Shi et al., 2015). These findings, together
with those showing that sebaceous lipids are important reg-
ulators of the growth of cutaneous microbiota (Pappas, 2009),
collectively suggest that controlled, moderate “sebostimula-
tion” (ideally without altering the physiological composition
of the sebum) may be beneficial in diseases characterized by
skin dryness.
eCB signaling, a recently emerging regulator of cutaneous
biology (Maccarrone et al., 2015), appears to be a very
promising subject of study in this field. We have previously
shown that (i) human sebocytes are able to produce the two
major eCBs (AEA and 2-AG); (ii) CB2 receptor-coupled
signaling contributes to the maintenance of homeostatic
SLP; and (iii) direct AEA or 2-AG treatments dramatically
increase lipogenesis (Dobrosi et al., 2008). On the other
hand, (e)-cannabidiol and several further nonpsychotropic
phytocannabinoids (e.g., (e)-D9-tetrahydrocannabivarin)
were shown to normalize arachidonic acid- and other
mediator-induced excessive lipid synthesis and exerted
complex (combined lipostatic, anti-proliferative, and anti-
inflammatory) anti-acne effects, whereas others (namely
(e)-cannabigerol and (e)-cannabigerovarin) were able to
slightly but significantly promote SLP (Ola´h et al., 2014,
2016b). Hence, in this study we aimed to unveil hidden as-
pects of the ECS of human sebocytes.
Here, we provide evidence that major members of the ECS
(i.e., NAPE-PLD, DAGLa and -b, MAGL, and FAAH) are
expressed both in vitro in human sebocytes (see
Supplementary Figure S1aed) and (with the sole exception of
DAGLa, which exhibited a dubious immunostaining pattern),
also in situ in SGs of the human skin (Figure 1), which nicely
confirms the available murine data of MAGL (Ma et al., 2011)
and FAAH (Wohlman et al., 2016) expression in SGs.
Moreover, besides the expression of the enzymes, we could
also show that eCB transport is functionally active and
pharmacologically inhibitable in human sebocytes
(Figure 2a). This process is more likely to be involved in (re-)
uptake/degradation rather than synthesis/release of the eCBs,
because VDM11 (10 mmol/L for 24 hours) significantly
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elevated AEA levels in the samples and tended to increase 2-
AG concentration as well. Although this compound was
proven to only negligibly alter FAAH activity in sebocytes
(see Supplementary Table S1), we also observed a significant
elevation in OEA levels and a tendency toward increase in
PEA concentrations (Figure 2bee).
Next, we tested the effects on the viability, lipid synthesis,
and immune responses of human sebocytes. We found that
noncytotoxic concentrations of VDM11 and AM404 (see
Supplementary Figures S3, S4a, and S7) induced a moderate
but significant increase in SLP (Figure 3a, and see
Supplementary Figure S4b) and that VDM11 interfered with
the proinflammatory effects of LPS (Figure 3b and c). Certain
sebocyte-derived cytokines (e.g., IL-6) can induce differenti-
ation of CD4þ/CD45RAþ naı¨ve T cells into T helper type 17
cells (Mattii et al., 2017), further supporting the concept that
dysregulation of sebocyte biology can contribute not only to
the development of acne, but also to other (partly) T helper
type 17-driven inflammatory dermatoses, such as AD or
psoriasis. Thus, the suppression of IL-6 expression and release
that we have shown here (Figure 3b and c) is likely to be
clinically relevant and promises to be beneficial in such
conditions.
Collectively, these findings strongly suggest that abrogation
of eCB degradation of sebocytes, and the subsequent eleva-
tion of the “eCB-tone,” promotes SLP. However, quite unex-
pectedly, by using the FAAH inhibitor URB597, we found
that, although it was successful in suppressing the FAAH
activity of the sebocytes (see Supplementary Table S1), it had
no effect on SLP (Supplementary Figure S5). An explanation
of this unexpected finding remains to be uncovered in future
targeted studies but may lie in the fact that relatively low
levels of FAAH activity (measured as the capability of cell
membranes to hydrolyze radiolabeled AEA) was detected in
SZ95 sebocytes. Further possible interpretations about the
possible underlying mechanisms are presented in the
Supplementary Materials online.
As discussed, a moderate (i.e., not excessive, seborrheic/
acnegenic) elevation of physiological SLP would be highly
desirable in the management of diseases accompanied by
skin dryness (e.g., AD) (Pappas, 2009; Shi et al., 2015). The
fact that the lipogenic effect of VDM11 was far weaker than
those usually seen upon direct AEA (Figure 3a) or other
lipogenic (e.g., 2-AG, arachidonic acid, and linoleic acid þ
testosterone) treatments (Dobrosi et al., 2008; Ge´czy et al.,
2012; Ola´h et al., 2014, 2016b), together with our reported
anti-inflammatory effect (Figure 3b and c), indicates that
VDM11 (and maybe other eCB transport inhibitors) may be
beneficial in treating such diseases. Obviously, however, the
exact impact of VDM11 treatment on the sebaceous lip-
idome must be thoroughly investigated in future specific
studies to exclude the possibility of its potential acnegenic
transformation.
Anti-inflammatory effects of elevated eCB tone are not
unprecedented in either murine or human skin. Since the
groundbreaking work of Karsak et al. (2007), many other
studies have shown that the homeostatic ECS is one of the
master regulators of cutaneous immune responses, keeping
under control local allergic and inflammatory processes
(Ola´h et al., 2016a).
Moreover, the fact that VDM11 could significantly increase
OEA and tended to elevate PEA levels (Figure 2d and e)
highlights the possibility that SGs may contribute to the
cutaneous PEA and OEA metabolism and supply of their local
micromilieu with these pleiotropic anti-inflammatory mole-
cules (Facci et al., 1995; Impellizzeri et al., 2015; Pontis
et al., 2016; Yang et al., 2016). Based on these data, there
is a possibility that SG hypoplasia and hypofunction observed
in AD (Shi et al., 2015) may be accompanied not only by
reduced sebum production, but also by impaired PEA (and/or
OEA) supply, which might contribute to the development and
worsening of atopic inflammation. Because a PEA-containing
cream was recently shown to efficiently alleviate symptoms
of AD patients (ATOPA study, Eberlein et al., 2008), clinical
studies are urgently invited to explore the possible role of SG
hypoplasia-derived putative PEA/OEA deficiency in the
development of AD symptoms. Further speculations about
the possible role and targets of PEA and OEA are mentioned
in the Supplementary Materials.
Our findings show that (i) human sebocytes express the
most important enzymes involved in eCB and eCB-like
mediator metabolism; (ii) human sebocytes are involved in
the cutaneous metabolism of PEA and OEA; (iii) VDM11
increases or tends to increase the levels of eCBs and related
acylethanolamides; (iv) VDM11 induces a moderate increase
in SLP; and (v) VDM11 induces remarkable anti-
inflammatory actions in human sebocytes (see
Supplementary Figure S8 online). Thus, human SGs may be
important in regulating the supply of key eCBs and related
acylethanolamides to their tissue microenvironment, and
targeting the ECS holds out promise to control cutaneous
inflammation. All in all, our data should encourage the
exploitation of selected, SG-targeting ECS modulators in
appropriate clinical trials to alleviate symptoms of cutaneous
diseases (e.g., AD) characterized by skin dryness and
inflammation.
MATERIALS AND METHODS
Detailed descriptions of the applied materials and methods can be
found in the Supplementary Materials. Briefly, lipid synthesis was
investigated by fluorescent Nile Red staining, and viability and cell
death were assessed by MTT assay and combined fluorescent
DilC1(5)-SYTOX Green labeling, respectively. Gene expression was
studied by quantitative PCR (mRNA level), ELISA, Western blot, and
immunohistochemistry (protein level). The uptake of AEA into cells
was determined by measuring the cellular uptake of radiolabeled
AEA, as described before (Nicolussi et al., 2014a, 2014b), whereas
levels of the eCBs were quantified by isotope dilution-liquid chro-
matography coupled with single quadrupole mass spectrometric
analysis (Marsicano et al., 2002), and FAAH activity was determined
according to our previously established and optimized protocol
(Ortar et al., 2003). Data were analyzed by Origin Pro Plus 6.0
software (Microcal, Northampton, MA) using the Student two-tailed,
unpaired t test, and P-values less than 0.05 were regarded as sig-
nificant differences. Graphs were plotted by using Origin Pro Plus
6.0 software. Primary human material was collected after obtaining
written informed consent, adhering to the Helsinki Declaration, and
after obtaining permission from the Institutional Research Ethics
Committee and Government Office for Hajdu´-Bihar County
N Za´ka´ny et al.
Sebocyte Endocannabinoid System
Journal of Investigative Dermatology (2018), Volume 1381704






CCZ owns an international patent on the SZ95 sebaceous gland cell line
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eicosatetraenamide) and AM404 (N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-
eicosatetraenamide) together with AEA were purchased from Cayman Chemical 
Company (Ann Arbor, MI, USA). URB597 (Cyclohexylcarbamic acid 3'-
(Aminocarbonyl)-[1,1'-biphenyl]-3-yl ester) and UCM707 ((5Z,8Z,11Z,14Z)-N-(3-
Furanylmethyl)-5,8,11,14-eicosatetraenamide) were obtained from were obtained from 
Tocris Bioscience (Bristol, UK) or Cayman Chemical Company (Ann Arbor, MI, USA 
and Tallinn, Estonia; in case of AEA uptake assay); [ethanolamine-1-3H]-AEA (60 
Ci/mmol) was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, 
USA); whereas manufacturer of γ-irradiated lipopolysaccharide from Escherichia coli 
026:B6 (LPS) was Sigma-Aldrich (St. Louis, MO, USA), respectively. LPS was 
dissolved in filtered distilled water. The solvent of all other compounds was absolute 
ethanol (Sigma-Aldrich) except for the [3H]-AEA uptake assay where UCM707 was 




Human immortalized SZ95 sebocytes, originated from human facial sebaceous glands 
(Zouboulis et al., 1999; Tóth et al., 2011; Zouboulis et al., 2014), were cultured in 
Sebomed® Basal Medium (Biochrom, Berlin, Germany) supplemented with 10 (V/V)% 
fetal bovine serum (Life Technologies Hungary Ltd., Budapest, Hungary), 1 mM CaCl2, 
5 ng/ml human epidermal growth factor (Sigma-Aldrich), MycoZap™ Plus-CL (1:500; 
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Lonza, Budapest, Hungary). The medium was changed every other day, and cells were 
sub-cultured at 60-70% confluence. 
 
Determination of intracellular lipids 
For quantitative measurement of sebaceous (neutral) lipid content, cells (20,000 
cells/well) were cultured in 96-well “black-well/clear-bottom” plates (Greiner Bio-One, 
Frickenhausen, Germany) in quadruplicates, and were treated with compounds as 
indicated. Subsequently, supernatants were discarded, cells were washed twice with 
phosphate-buffered saline (PBS; 115 mM NaCl, 20 mM Na2HPO4, pH 7.4; all from 
Sigma-Aldrich), and 100 μl of a 1 μg/ml Nile Red (Sigma-Aldrich) solution in PBS was 
added to each well. The plates were then incubated at 37°C for 20 min, and fluorescence 
was measured on FlexStation 3 multi-mode microplate reader (Molecular Devices, San 
Francisco, CA, USA). Results are expressed as percentage of the relative fluorescence 
units in comparison with the vehicle controls using 485 nm excitation and 565 nm 
emission wavelengths. 
 
Determination of cellular viability 
The viability of the cells was determined by measuring the conversion of the 
tetrazolium salt MTT (Sigma-Aldrich) to formazan by mitochondrial dehydrogenases. 
Cells were plated in 96-well plates (20,000 cells/well) in quadruplicates, and were 
treated as indicated for 2 days. Cells were then incubated with 0.5 mg/ml MTT for 2 
hrs, and concentration of formazan crystals (as an indicator of number of viable cells) 
was determined colorimetrically at 565 nm by using FlexStation 3 multi-mode 
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microplate reader (Molecular Devices). Results were expressed as percentage of vehicle 
controls regarded as 100%. 
 
Determination of apoptosis 
A decrease in the mitochondrial membrane potential is one of the earliest markers of 
apoptosis (Green and Reed, 1998; Susin et al., 1998). Therefore, to assess the process, 
mitochondrial membrane potential of SZ95 sebocytes was determined using 
1,1′,3,3,3′,3′-hexamethylindodicarbo-cyanine iodide containing MitoProbe™ DilC1(5) 
Assay Kit (Life Technologies Hungary Ltd.). Cells (20,000 cells/well) were cultured in 
96-well “black-well/clear-bottom” plates (Greiner Bio One) in quadruplicates and were 
treated as indicated for 48 hrs. After removal of supernatants, cells were incubated for 
30 minutes with DilC1(5) working solution (50 μl/well), then washed with PBS, and the 
fluorescence of DilC1(5) was measured at 630 nm excitation and 670 nm emission 
wavelengths using FlexStation 3 multi-mode microplate reader (Molecular Devices). 
Relative fluorescence values were expressed as percentage of vehicle controls regarded 
as 100%. As a positive control for apoptosis, we applied carbonyl cyanide m-
chlorophenyl hydrazone (CCCP; Life Technologies Hungary Ltd.) dissolved in the 
DilC1(5) working solution (1:200 for 30 min). 
 
Determination of necrosis 
Necrotic processes were determined by SYTOX Green staining (Life Technologies 
Hungary Ltd.). The dye is able to penetrate (and then bind to the nucleic acids) only to 
necrotic cells with ruptured plasma membranes, whereas healthy cells with intact 
surface membranes show negligible SYTOX Green staining. Cells were cultured in 96-
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well “black-well/clear-bottom” plates (Greiner Bio One), and treated as indicated for up 
to 48 hrs. Supernatants were then discarded, and the cells were incubated for 30 minutes 
with 1 μM SYTOX Green dye. Following incubation, cells were washed with PBS, the 
culture medium was replaced, and fluorescence of SYTOX Green was measured at 490 
nm excitation and 520 nm emission wavelengths using FlexStation 3 multi-mode 
microplate reader (Molecular Devices). Relative fluorescence values were expressed as 
percentage of vehicle controls regarded as 100%. As a positive control for necrosis, 
lysis buffer (1:100 in the SYTOX Green working solution for 30 min; Life 
Technologies Hungary Ltd.) was applied. 
Due to their spectral properties, DilC1(5) and SYTOX Green dyes were always 
administered together, enabling us to investigate necrotic and early apoptotic processes 
of the same cultures. Selective decrease of DilC1(5) intensity indicated mitochondrial 
depolarization (i.e. the onset of early apoptotic processes), whereas increase of SYTOX 
Green staining intensity revealed necrotic cell death. 
 
RNA isolation, reverse transcription and quantitative “real-time” PCR (Q-PCR) 
Q-PCR was performed on an ABI Prism 7000 sequence detection system (Applied 
Biosystems, Foster City, CA, USA) or Stratagene Mx3005P QPCR System (Agilent 
Technologies, Santa Clara, CA, USA) using the 5’ nuclease assay. Total RNA was 
isolated using TRIzol (Life Technologies Hungary Ltd.), DNase treatment was 
performed according to the manufacturer’s protocol, and then 1 μg of total RNA was 
reverse-transcribed into cDNA by using High Capacity cDNA Kit from Life 
Technologies Hungary Ltd. PCR amplification was performed by using the TaqMan 
primers and probes (assay IDs: Hs00174092_m1 for interleukin [IL]-1α, 
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Hs00174097_m1 for IL-1β, Hs00985639_m1 for IL-6, Hs00174103_m1 for IL-8, 
Hs00174128_m1 for tumor necrosis factor [TNF]-α; Hs00419593_m1 for NAPE-PLD; 
Hs00391374_m1 for DAGLα; Hs00373700_m1 for DAGLβ, Hs00155015_m1 for 
FAAH and Hs00200752_m1 for MAGL) and the TaqMan universal PCR master mix 
protocol (Applied Biosystems). As internal control, transcripts of 18S RNA or 
peptidylprolyl isomerase A (PPIA) were determined (assay IDs: Hs03928905_g1 and 
Hs99999905_m1, respectively). The amount of the transcripts was normalized to those 
of the housekeeping gene using the ΔCT method. Finally, when indicated, the results 
were further normalized to the expression of the vehicle control (ΔΔCT method). 
 
Determination of cytokine release (ELISA) 
500,000 cells were seeded in Petri-dishes (d=15 mm) in 1.5 ml culture medium. On the 
next day, cells were treated as indicated. Supernatants were collected, and the released 
amounts of IL-1α, IL-1β, IL-6, IL-8, and TNFα were determined according to the 
manufacturers’ (IL-1β, IL-6, IL-8, and TNFα: BD Pharmingen, Franklin Lakes, NJ, 
USA; IL-1α: R&D Systems, Inc., Minneapolis, MN, USA) protocols. In case of IL-6 
and IL-8, supernatants were diluted (1:50), whereas for the other three cytokines, non-
diluted supernatants were used. 
 
Western blotting 
Cells were harvested in lysis buffer (20 mM Tris-HCl, pH 7.4, 5 mM EGTA, 1 mM 4-
(2-aminoethyl) benzensulphonyl fluoride, protease inhibitor cocktail diluted 1:100, (all 
from Sigma-Aldrich) and the protein content was measured by a modified BCA protein 
assay (Pierce, Rockford, IL, USA). The samples were then subjected to sodium dodecyl 
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sulphate-polyacrylamide gel electrophoresis. 10% Mini Protean TGX gels (Bio-Rad, 
Hercules, CA, USA) were loaded with equal (40 μg) amount of protein per lane. 
Samples were then transferred to nitrocellulose membranes, by using Trans-Blot® 
Turbo™ Nitrocellulose Transfer Packs and Trans-Blot Turbo™ System (both from Bio-
Rad), and then probed with mouse-anti-human FAAH, rabbit-anti-human NAPE-PLD, 
MAGL and DAGLα (all from Abcam, Camebridge, UK), or goat-anti-human DAGLβ 
(Santa Cruz Inc., Heidelberg, Germany) specific primary antibodies (all overnight at 
4°C in 1:200 in 5% milk containing PBS). As secondary antibody, horseradish 
peroxidase-conjugated rabbit IgG Fc segment-specific antibodies (developed in goat, 
1:1000 in 5% milk containing PBS, Bio-Rad) were used, and the immunoreactive bands 
were visualized by a SuperSignal® West Pico Chemiluminescent Substrate enhanced 
chemiluminescence kit (Pierce) using a KODAK Gel Logic 1500 Imaging System 
(Eastman Kodak Company, Kodak, Tokyo, Japan). 
 
Immunohistochemistry 
The immunohistochemical investigation of NAPE-PLD, FAAH, MAGL (Novus 
Biologicals, Littleton, USA) and DAGLβ (Bioss Inc., Massachusetts, USA) was 
performed on 3 formalin fixed paraffin embedded, skin samples rich in sebaceous 
glands, all diagnosed as trichilemmal cyst. The expression pattern of DAGLα (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) in sebaceous gland was examined on 3 
frozen skin samples obtained from vertex. 
 
Serial 4 μm thick sections were cut from paraffin blocks and frozen tissues as well. 
Frozen sections were then fixed in pre-cooled acetone for 10 min, whereas heat-induced 
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antigen retrieval was performed on formalin fixed samples. FAAH, MAGL, and 
DAGLβ epitopes were retrieved in 11 mM citrate buffer (pH 6) applied in pressure 
cooker for 2 min on full pressure. NAPE-PLD was retrieved in EnVision FLEX Target 
Retrieval Solution High pH (DAKO, Glostrup, Denmark) in water bath for 30 min at 95 
°C. Endogenous peroxidase activity was blocked with 3% H2O2 for 10 minutes in case 
of formalin fixed and frozen sections as well. After blocking, tissue sections were 
incubated at room temperature with primary antibodies diluted in 1% Bovine Serum 
Albumin (Sigma-Aldrich, St. Louis, MO, USA): NAPE-PLD (mouse, clone: 5F7, 1:75, 
60 min), FAAH (rabbit polyclonal, 1:20, 60 min), MAGL (mouse, clone: 2B11, 1:100, 
60 min), DAGLα (rabbit polyclonal, 1:100, 30 min), DAGLβ (rabbit polyclonal, 1:50, 
30 min). Sections were then incubated with the EnVision FLEX Labeled polymer-HRP 
anti-rabbit and anti-mouse System (DAKO, Glostrup, Denmark) at room temperature 
for 30 min with 3,3’-diaminobenzidine (DAB) visualization techniques. Cell nuclei 
were counterstained with hematoxylin and tissue sections were finally mounted in 
permanent mounting medium (Histolab, Göteborg, Sweden). 
 
Tissues with known antigen expression pattern were used in every staining run as 
positive controls (Supplementary Figure S2). Renal tubules served as positive controls 
for NAPE-PLD (expected positivity: membranes of the proximal tubules according to 
The Human Protein Atlas http://www.proteinatlas.org/ENSG00000161048-
NAPEPLD/tissue) and MAGL (expected positivity: nuclei in all tubules; Labar et al., 
2010) detection. Testis was used to validate FAAH expression (expected positivity: 
cytoplasmic staining in Leydig cells and in testicular tubules; Scotchie et al., 2015), and 
cerebellum was applied as a positive control for DAGLα (expected positivity: dendritic 
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tree of Purkinje cells; Bisogno et al., 2003) and DAGLβ (expected positivity: synaptic 
areas; Bisogno et al., 2003). Negative controls were obtained by omitting the primary 
antibody in all cases. 
 
[3H]-AEA uptake assay in SZ95 sebocytes 
The cellular uptake of AEA in SZ95 sebocytes was determined using an established 
multi-phase assay protocol previously described for different cell types (Nicolussi et al., 
2014a; Nicolussi et al., 2014b, Rau et al. 2014). Briefly, 1 Mio. SZ95 sebocytes per 
sample were incubated with either the vehicle control DMSO (5 µL) or the reference 
AEA uptake inhibitor UCM707 (5 µL, 10 µM final) in a volume of 500 µL RPMI, 37°C 
in AquaSilTM silanized screw-cap Eppendorf tubes. After 15 min of incubation at 37°C 
a mixture of [ethanolamine-1-3H]AEA (0.5 nM) and unlabelled AEA (final 100 nM) in 
5 µL EtOH was added for 15 min. The uptake process was stopped by putting the 
samples on ice following rapid centrifugation at 800 x g for 5 min at 4°C. The 
supernatant was collected separately and the cell pellet was washed and resuspended 
using 500 µL ice-cold PBS containing 1 % BSA (fatty acid-free). The washing solution 
was collected and pooled with the organic phase extracted from the primary supernatant 
after phase separation (1:1 CHCl3:MeOH, ice cold, 1 mL, 10’000 x g) resulting in the 
extracellular phase. The aqueous phase was collected separately. The cell pellet was 
resuspended in 250 µL PBS. All phases were transferred into scintillation tubes and 
merged with Ultima Gold scintillation cocktail following liquid scintillation counting 
(LCS) using a Packard Tri-Carb 2100 TR beta counter. Data are reported as mean 
values of n = 3 independent experiments performed in triplicates. 
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PBS, RPMI and BSA fatty acid free was ordered from Sigma-Aldrich, Switzerland. 
Ultima Gold liquid scintillation cocktail was purchased from Perkin Elmer, Switzerland. 
AquaSilTM silanization fluid was purchased from Thermo Fisher Scientific, USA. 
 
Determination of the endocannabinoid levels 
Cells were seeded to Petri dishes in 5 million/5 ml culture medium/Petri dish density, 
and were treated with VMD11 or vehicle for 24 hours (5 ml medium/dish). At the end 
of the treatment, equal amount (i.e. 5 ml) of ice-cold methanol was added to the 
cultures, and the samples (cells and their supernatants together) were harvested and 
immediately stored at -80°C for further analysis. 
The samples, which contained both cells and their supernatants were homogenized in a 
solution containing 5 pmol of [2H]8-AEA and 50 pmol of [
2H]5-2-AG, [
2H]4-PEA and 
[2H]2-OEA. The lipid-containing organic phase was pre-purified by open-bed 
chromatography on silica gel (Bisogno et al., 1997) and analyzed by LC-APCI-MS 
(Marsicano et al., 2002). AEA, 2-AG, PEA and OEA amounts (pmol) were normalized 
per mg of extracted lipids. 
 
Assessment of the FAAH-activity 
Sebocytes were trypsinized, and following determination of the cell count, and removal 
of the supernatant, they were transferred to -80°C for further analyses.  
Cell pellet homogenates in 50 mM Tris-HCl, pH 7.4 were incubated for 30 min at 37°C 
with [14C]AEA (2 μM) and with test compounds, VDM11, URB 597, UCM 707. 
[14C]Ethanolamine produced from [14C]AEA hydrolysis was measured by scintillation 
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counting of the aqueous phase after extraction of the incubation mixture with 2 vol. of 
CHCl3/CH3OH 2:1 (by vol.). 
 
Statistical analysis 
Data were analyzed by Origin Pro Plus 6.0 software (Microcal, Northampton, MA, 
USA), using Student’s two tailed, two samples t-test and P<0.05 values were regarded 




SUPPLEMENTARY DISCUSSION 1 – Alternative interpretation of differential 
effects of EMT- and FAAH-inhibitors 
Since, at least in some cells, the possibility that EMT-inhibitors also block the release of 
eCBs cannot be excluded (Chicca et al., 2012), one should also take into consideration 
that the effects of VDM11 were generated via intracellular signaling pathways. 
 
Indeed, there is a possibility that, in case of human sebocytes, under homeostatic 
conditions, rather than being up-taken, eCBs are transported out of the cells by EMT. 
EMT-inhibitors would block this process, and as a consequence, eCBs would be 
degraded more intracellularly leading to a FAAH-mediated increase in the cytoplasmic 
arachidonic acid (AA; an important precursor of several pro-inflammatory lipid 
mediators; Bennett and Gilroy 2016) level. AA has been previously shown to greatly 
increase lipogenesis (see e.g. Géczy et al. 2012). Following this line, one may speculate 
that lipogenic action of VDM11 could be mediated by the elevation of the intracellular 
AA levels, whereas lack of URB597’s efficiency could be explained by the lack of such 
AA-elevation. 
 
Although this hypothesis is very intriguing, several lines of evidence go against it. First, 
we have previously found that AEA’s lipogenic effect was CB2-dependent (Dobrosi et 
al. 2008), and AA does not activate CB2 (Di Marzo 2008). Second, cyclooxygenase and 
lipoxygenase metabolites of AA are more likely to exert pro-inflammatory effect 
(Bennett and Gilroy 2016), but we showed that VDM11 suppressed LPS-induced pro-
inflammatory response (Figure 3). Third, if exogenously applied AEA indeed needed to 
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be intracellularly converted to AA in order to promote SLP, VDM11 should have 
prevented its lipogenic action, but it had no effect on it (Supplementary Figure S6).  
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SUPPLEMENTARY DISCUSSION 2 – Possible targets of PEA and OEA in the 
SGs 
Our results also point towards new, exciting possibilities with respect to the 
“cutannabinoid” system. Since our data argue for that not only AEA and 2-AG, but also 
PEA and OEA are metabolized in human sebocytes, one may speculate that these 
molecules might regulate yet un-identified, novel signaling pathways through activation 
of e.g. peroxisome proliferator-activated receptors (PPAR) or the recently de-
orphanized GPR55 and GPR119 receptors (Godlewski et al. 2009; Maccarrone et al. 
2015) in human sebocytes. Although the role of PPARs in regulating SG biology is 
already well-described (Dobrosi et al. 2008; Dozsa et al. 2016; Dozsa et al. 2014; 
Rosenfield et al. 1998), the expression of GPR55 and GPR119 is still unknown. 
Systematic studies are therefore needed to investigate the expression and putative role 
of these novel receptors in the biology of human SGs and, in a wider sense, in 
cutaneous (patho)physiology, with special emphasis on the development of 





Supplementary Figure S1 Major enzymes of the endocannabinoid metabolism are 
expressed in SZ95 sebocytes 
(a and c) Q-PCR on SZ95 sebocyte samples harvested at different confluences. Data of 
NAPE-PLD, DAGLα and –β, as well as MAGL and FAAH mRNA expressions were 
normalized to the level of peptidylprolyl isomerase A (PPIA) of the same sample, and 
are expressed as mean±SD of three determinations. One additional experiment yielded 
similar results. (b and d) Western blot analysis of lysates of SZ95 sebocytes (pc: post-
confluent culture). DAGL: diacylglycerol lipase; FAAH: fatty acid amide hydrolase; 
MAGL: monoacylglycerol lipase; NAPE-PLD: N-acyl phosphatidylethanolamine-


























































































Supplementary Figure S2 Optimization of the histological methods: labeling of the 
positive control tissues 
Immunohistochemistry of appropriate human tissues (DAGLα and –β: cerebellum; 
FAAH: testicle; MAGL and NAPE-PLD: kidney) was performed as described in the 
DAGLα (100x) DAGLα (400x) DAGLα (NC)
DAGLβ (100x) DAGLβ (400x) DAGLβ (NC)
NAPE-PLD (100x) NAPE-PLD (400x) NAPE-PLD (NC)
FAAH (100x) FAAH (400x) FAAH (NC)
MAGL (100x) MAGL (400x) MAGL (NC)
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Supplementary Methods section. Specific immunopositivity was visualized by 3,3’-
diaminobenzidine (DAB; brown color), whereas nuclei were counterstained by 
hematoxylin (blue color). Original magnifications: 100x (left column), 400x (middle 
and right columns); scale bars: 200 µm (left column) and 50 µm (middle and right 
columns). Negative controls (right column) were obtained by omitting the primary 
antibody in all cases. DAGL: diacylglycerol lipase; FAAH: fatty acid amide hydrolase; 
MAGL: monoacylglycerol lipase; NAPE-PLD: N-acyl phosphatidylethanolamine-





Supplementary Figure S3 Up to 10 µM, VDM11 did not decrease viability of human 
sebocytes 
Viability of SZ95 sebocytes was monitored by MTT-assay following 48-hr treatments. 
Results are expressed in the percentage of the vehicle control (100%, solid line) as 
mean±SEM of four independent determinations. One additional experiment yielded 
similar results. ** marks significant (P<0.01) difference compared to the vehicle 
control. n.s.: not significant difference. (When applied at higher concentrations, VDM11 
































Supplementary Figure S4 Similar to VDM11, a non-cytotoxic concentration of AM404 
moderately, but significantly increases sebaceous lipid synthesis 
(a) Viability of SZ95 sebocytes was monitored by MTT-assay following 48-hr 
treatments. Results are expressed in the percentage of the vehicle control (100%, solid 
line) as mean±SEM of four independent determinations. One additional experiment 
yielded similar results; n.s.: not significant difference. (b) Sebaceous lipid production of 
SZ95 sebocytes was assessed by Nile Red staining following 48-hr treatments. Results 
are expressed in the percentage of the vehicle control (100%, solid line) as mean±SEM 
of four independent determinations. One additional experiment yielded similar results. 




























































Supplementary Figure S5 In contrast to the effects of the EMT-inhibitors, URB597 
does not influence sebaceous lipid synthesis 
(a) Viability of SZ95 sebocytes was monitored by MTT-assay following 48-hr 
treatments. Results are expressed in the percentage of the vehicle control (100%, solid 
line) as mean±SEM of four independent determinations. One additional experiment 
yielded similar results; n.s.: not significant difference. (b) Sebaceous lipid production of 
SZ95 sebocytes was assessed by Nile Red staining following 48-hr treatments. Results 
are expressed in the percentage of the vehicle control (100%, solid line) as mean±SEM 
of four independent determinations. One additional experiment yielded similar results. 































































Supplementary Figure S6 The AEA uptake inhibitor VDM11 does not further increase 
lipogenic action of AEA 
Sebaceous lipid production of SZ95 sebocytes was assessed by Nile Red staining 
following 48-hr treatments. Results are expressed in the percentage of the vehicle 
control (100%, solid line) as mean±SEM of four independent determinations. One 








































Supplementary Figure S7 The most effective lipogenic concentration of VDM11 tends 
to decrease mitochondrial membrane potential 
Apoptotic and necrotic cell death of SZ95 sebocytes was investigated by DilC1(5)-
SYTOX Green double labeling following the indicated 48-hr treatments. As apoptosis 
positive control, carbonyl cyanide m-chlorophenyl hydrazone (CCCP; a well-known un-
coupler of the mitochondrial inner membrane) was applied (1:200 for 30 min), whereas 
necrosis was induced by lysis buffer (1:100 for 30 min). In general, selective decrease 
of DilC1(5) intensity indicates the development of “pure” apoptotic processes, whereas 
simultaneous increase of SYTOX Green level points to necrosis. Results are expressed 
in the percentage of the vehicle or positive controls (DilC1(5) and SYTOX Green, 
respectively) as mean±SEM of four independent determinations. One additional 
experiment yielded similar results. ** and *** mark significant (P<0.01 or 0.001, 
respectively) differences compared to the vehicle control. n.s.: not significant 
difference.  
**
SYTOX Green: membrane permeability
(positive control = 100%; ↑: necrosis)
DilC1(5): mitochondrial membrane potential




















Supplementary Figure S8 Overview of the human sebaceous glands’ endocannabinoid 
system, and the effects of VDM11 
Sebocytes express the major synthesizing (NAPE-PLD, DAGLα and –β) and degrading 
(MAGL, FAAH) enzymes of the eCB metabolism, and they metabolize several 
“classical” eCBs (AEA and 2-AG) as well as related acylethanolamides (PEA and 
OEA). Elevation of their levels by administration of VDM11 leads to a moderate 
increase of the sebaceous lipid production, and remarkable anti-inflammatory actions. 
Although AEA and 2-AG were shown to act through a CB2-coupled signaling pathway 
leading to PPAR activation (Dobrosi et al, 2008), expression of the cellular targets of 
PEA and OEA (e.g. GPR55 and GPR119) are still unknown in human sebocytes. 
2-AG: 2-arachidonlglycerol; AEA: N-arachidonoylethanolamine (anandamide); CB2: 
cannabinoid receptor 2; DAGL: diacylglycerol lipase; eCB: endocannabinoid; EMT: 
(putative) endocannabinoid membrane transporter; FAAH: fatty acid amide hydrolase; 


























Regulation of the tissue micromilieu?




receptors of PEA and OEA, respectively); MAGL: monoacylglycerol lipase; NAPE-
PLD: N-acyl phosphatidylethanolamine-specific phospholipase D; OEA: 
oleoylethanolamide; PEA: palmitoylethanolamide; PPAR: peroxisome proliferator-





Supplementary Table S1: Comparative assessment of FAAH-inhibitory capabilities of 
selected EMT- and FAAH-inhibitors on human SZ95 sebocytes 
Compounds Inhibition % 
(n=6) 
URB597 0.1 µM 66.1 ± 5.2  
VDM11 5 µM 22.0 ± 1.9 
VDM11 10 µM 20.9 ± 4.5 
VDM11 25 µM -8.5 ± 0.8 
(stimulation) 
UCM707 5 µM 4.9 ± 0.4 
UCM707 10 µM 26.4 ± 4.1 
UCM707 25 µM 20.1 ± 3.5 
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